Dataset Information

Analysis of skeletal muscle from a tailored pig model of Duchenne muscular dystrophy

ABSTRACT: We recently generated a novel genetically engineered pig model displaying the fundamental biochemical, clinical and pathological hallmarks of human DMD. To get insight into the hierarchy of molecular derangements during progression of muscular dystrophy, we performed a label free proteome analysis of biceps femoris muscle samples from 2-day-old and 3-month-old DMD and WT pigs.

INSTRUMENT(S): LTQ Orbitrap

ORGANISM(S): Sus Scrofa Domesticus (domestic Pig)

TISSUE(S): Biceps Femoris

DISEASE(S): Duchenne Muscular Dystrophy

SUBMITTER: Thomas Fröhlich

LAB HEAD: Thomas Fröhlich

PROVIDER: PXD002918 | Pride | 2016-09-27

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 15

Publications

Progressive muscle proteome changes in a clinically relevant pig model of Duchenne muscular dystrophy.

Fröhlich Thomas T Kemter Elisabeth E Flenkenthaler Florian F Klymiuk Nikolai N Otte Kathrin A KA Blutke Andreas A Krause Sabine S Walter Maggie C MC Wanke Rüdiger R Wolf Eckhard E Arnold Georg J GJ

Scientific reports 20160916

Duchenne muscular dystrophy (DMD) is caused by genetic deficiency of dystrophin and characterized by massive structural and functional changes of skeletal muscle tissue, leading to terminal muscle failure. We recently generated a novel genetically engineered pig model reflecting pathological hallmarks of human DMD better than the widely used mdx mouse. To get insight into the hierarchy of molecular derangements during DMD progression, we performed a proteome analysis of biceps femoris muscle sam ...[more]

PMID: 27634466

Similar Datasets

Project description:Absence of the dystrophin gene in Duchenne muscular dystrophy (DMD) results in the degeneration of skeletal and cardiac muscles. Owing to advances in respiratory medicine, cardiomyopathy has become a significant aspect of the disease. While CRISPR/Cas9 genome editing technology holds great potential as a novel therapeutic avenue for DMD, little is known about the efficacy of correction of DMD using the CRISPR/Cas9 system in mitigating the cardiomyopathy phenotype in DMD. To define the effects of CRISPR/Cas9 genome editing on structural, functional and transcriptional dysregulation in DMD-associated cardiomyopathy. We generated induced pluripotent stem cells (iPSCs) from a patient with a deletion of exon 44 of the DMD gene (ΔEx44) and his healthy brother. Here, we targeted exon 45 of the DMD gene by CRISPR/Cas9 genome editing to generate corrected DMD (cDMD) iPSC lines, wherein the DMD open reading frame was restored via reframing (RF) or exon skipping (ES). While DMD cardiomyocytes (CMs) demonstrated morphologic, structural and functional deficits compared to control CMs, CMs from both cDMD lines were similar to control CMs. Bulk RNA-sequencing of DMD CMs showed transcriptional dysregulation consistent with dilated cardiomyopathy, which was mitigated in cDMD CMs. We then corrected DMD CMs by adenoviral delivery of Cas9/gRNA and showed that postnatal correction of DMD CMs reduces their arrhythmogenic potential. Single-nucleus RNA-sequencing of hearts showed reduced transcriptional dysregulation in CMs and fibroblasts in corrected mice compared with DMD mice, consistent with reduced histopathologic changes.We show that CRISPR/Cas9-mediated correction of DMD ΔEx44 mitigates structural, functional and transcriptional dysregulation consistent with dilated cardiomyopathy irrespective of how the protein reading frame is restored. We show that these effects extend to postnatal editing in iPSC-CMs and mice. These findings provide key insights into the utility of genome editing as a novel therapeutic for DMD-associated cardiomyopathy.

			Action	DRS
	522_DMD_3Mo.raw	Raw
	527_DMD_3Mo.raw	Raw
	536_DMD_2d.raw	Raw
	537_DMD_3Mo.raw	Raw
	542_DMD_2d.raw	Raw